Pasithea net loss widens 41.9% to $5.27 million in Q2 2026 - KTTA News | RalliesPasithea net loss widens 41.9% to $5.27 million in Q2 2026
K
KTTA• Second-quarter results
- Pasithea Therapeutics posted a Q2 net loss of $5.27 million, widening 41.9% from a year earlier.
- Operating loss widened 49.9% to $5.71 million as research and development expense climbed 71.5% to $3.69 million.
- General and administrative costs increased 22% to $2.03 million, while other income rose to $439,430.
- For the first half, net loss widened 11.9% to $8.14 million as operating loss increased 41.4% to $10.59 million.
- Cash, cash equivalents and restricted cash fell about $9.5 million in the first half; it had about $45.7 million on hand at June 30.
•
